TY  - JOUR
AU  - de Bortoli, Till
AU  - Benary, Manuela
AU  - Horak, Peter
AU  - Lamping, Mario
AU  - Stintzing, Sebastian
AU  - Tinhofer, Ingeborg
AU  - Leyvraz, Serge
AU  - Schäfer, Reinhold
AU  - Klauschen, Frederick
AU  - Keller, Ulrich
AU  - Stenzinger, Albrecht
AU  - Fröhling, Stefan
AU  - Kurzrock, Razelle
AU  - Keilholz, Ulrich
AU  - Rieke, Damian T
AU  - Jelas, Ivan
TI  - Tumour mutational burden and survival with molecularly matched therapy.
JO  - European journal of cancer
VL  - 190
SN  - 0014-2964
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2023-01600
SP  - 112925
PY  - 2023
AB  - The impact of tumour mutational burden (TMB) on outcome with molecularly matched therapy is unknown. Higher TMB could predict resistance to molecularly matched therapy through co-occurring driver mutations.One hundred and four patients with advanced cancers underwent molecular profiling in the DKTK-MASTER program. Fifty-five patients received systemic therapy excluding immunotherapy. Patients with molecularly matched (n = 35) or non-molecularly informed therapy (n = 20) were analysed for TMB and survival. Results were validated in an independent cohort of patients receiving molecularly matched (n = 68) or non-molecularly informed therapy (n = 40). Co-occurring driver mutations and TMB were analysed in the exploratory cohort and The Cancer Genome Atlas (TCGA) datasets.Patients were stratified by the median TMB of 1.67 mutations per Megabase (mut/Mb) of 35 patients receiving molecularly matched therapy into TMB-high or TMB-low groups. Median overall survival (4 months [95
KW  - Molecular tumour board (Other)
KW  - Personalised therapy (Other)
KW  - Precision oncology (Other)
KW  - Tumour mutational burden (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37544709
DO  - DOI:10.1016/j.ejca.2023.05.013
UR  - https://inrepo02.dkfz.de/record/278343
ER  -